-
Mashup Score: 0Retinal Physician - SUBSPECIALTY NEWS: Retina changes seen in Alzheimer disease, research into new GA therapies, and more. - 12 month(s) ago
Researchers Map Retina Changes Corresponding to Early Alzheimer Disease ■ Cedars-Sinai investigators have produced the most extensive analysis to date of changes in the retina that correspond to brain and cognitive changes in patients with Alzheimer disease. Their analysis, published in Acta Neuropathologica, is a seminal step toward understanding the effects of Alzheimer disease on the retina,…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet
-
Mashup Score: 1Retinal Physician - SUBSPECIALTY NEWS: Retina changes seen in Alzheimer disease, research into new GA therapies, and more. - 12 month(s) ago
Researchers Map Retina Changes Corresponding to Early Alzheimer Disease ■ Cedars-Sinai investigators have produced the most extensive analysis to date of changes in the retina that correspond to brain and cognitive changes in patients with Alzheimer disease. Their analysis, published in Acta Neuropathologica, is a seminal step toward understanding the effects of Alzheimer disease on the retina,…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
OLiX Pharmaceuticals announced that the first patient has been successfully dosed in a phase 1 clinical trial evaluating OLX10212, an investigational RNAi therapeutic intended for the treatment of AMD. Read more in the Subspecialty News. https://t.co/LErYiO2bkz https://t.co/5j7bnHLPC1
-
-
Mashup Score: 0Retinal Physician - CLINICAL TRIAL UPDATE - 12 month(s) ago
DRY AMD Study: QA102 Phase II Study in Subjects With Dry AMD (AMEND) Clinicaltrials.gov Identifier: NCT05536752 Sponsor: Smilebiotek Zhuhai Limited Purpose: This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of GA or CNV in high-risk eyes. Design:…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Peruse all of the active clinical trials in AMD, DME, RVO, and uveitis in our Clinical Trial Update. https://t.co/KOOtXQO7QU https://t.co/627n8XebbM
-
-
Mashup Score: 1Retinal Physician - NEW PRODUCT APPLICATIONS: The First Drug to Treat Geographic Atrophy Debuts - 12 month(s) ago
Medication slows the progression of the disease.
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
The First Drug to Treat Geographic Atrophy Debuts: Syfovre slows the progression of disease. https://t.co/yyQsTeX2oo https://t.co/9bSLaC4IDW
-
-
Mashup Score: 0Retinal Physician - UVEITIS CORNER: Research on Uveitis in Survivors of Ebola Virus Disease - 12 month(s) ago
Two uveitis specialists share their experiences.
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Research on Uveitis in Survivors of Ebola Virus Disease: Two uveitis specialists share their experiences. https://t.co/XEKKjzYLt8 https://t.co/WE5uYHZZwZ
-
-
Mashup Score: 0
To avoid payment denials, make sure your chart notes include the “how” and “why” of each procedure.
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
CODING Q&A: Minor Surgery But Not Minor Documentation To avoid payment denials, make sure your chart notes include the “how” and “why” of each procedure. By Brandy H. Sperry, COMT, COE, OCS https://t.co/pwrNhsiz87 #ophthalmology https://t.co/y60MrZzMhd
-
-
Mashup Score: 0Retinal Physician - SUBSPECIALTY NEWS: Retina changes seen in Alzheimer disease, research into new GA therapies, and more. - 12 month(s) ago
Researchers Map Retina Changes Corresponding to Early Alzheimer Disease ■ Cedars-Sinai investigators have produced the most extensive analysis to date of changes in the retina that correspond to brain and cognitive changes in patients with Alzheimer disease. Their analysis, published in Acta Neuropathologica, is a seminal step toward understanding the effects of Alzheimer disease on the retina,…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
Iveric Bio announced an exploratory time-to-event analysis from the avacincaptad pegol GATHER clinical trial program evaluating reduction in vision loss with ACP 2 mg vs sham for #geographicatrophy. Read more in the Subspecialty News from the May issue. https://t.co/9cO6gudcum https://t.co/FIiIf2c7dR
-
-
Mashup Score: 0Retinal Physician - SUBSPECIALTY NEWS: Retina changes seen in Alzheimer disease, research into new GA therapies, and more. - 12 month(s) ago
Researchers Map Retina Changes Corresponding to Early Alzheimer Disease ■ Cedars-Sinai investigators have produced the most extensive analysis to date of changes in the retina that correspond to brain and cognitive changes in patients with Alzheimer disease. Their analysis, published in Acta Neuropathologica, is a seminal step toward understanding the effects of Alzheimer disease on the retina,…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
GenSight Biologics announced the publication of pooled safety data from 5 clinical studies with the #genetherapy lenadogene nolparvovec (Lumevoq) for ND4-LHON. Read more in the Subspecialty News from the May issue. https://t.co/9b0SAONi8B #ophthalmology https://t.co/FBoFvv3040
-
-
Mashup Score: 0Retinal Physician - SUBSPECIALTY NEWS: Retina changes seen in Alzheimer disease, research into new GA therapies, and more. - 12 month(s) ago
Researchers Map Retina Changes Corresponding to Early Alzheimer Disease ■ Cedars-Sinai investigators have produced the most extensive analysis to date of changes in the retina that correspond to brain and cognitive changes in patients with Alzheimer disease. Their analysis, published in Acta Neuropathologica, is a seminal step toward understanding the effects of Alzheimer disease on the retina,…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
EyePoint Pharmaceuticals announced it has completed enrollment in the phase 2 DAVIO 2 clinical trial evaluating EYP-1901 as a potential 6-month maintenance treatment for wet AMD. Read more in the Subspecialty News from the May issue. https://t.co/urPV45n0lB https://t.co/2EormyvXo4
-
-
Mashup Score: 0Retinal Physician - SUBSPECIALTY NEWS: Retina changes seen in Alzheimer disease, research into new GA therapies, and more. - 12 month(s) ago
Researchers Map Retina Changes Corresponding to Early Alzheimer Disease ■ Cedars-Sinai investigators have produced the most extensive analysis to date of changes in the retina that correspond to brain and cognitive changes in patients with Alzheimer disease. Their analysis, published in Acta Neuropathologica, is a seminal step toward understanding the effects of Alzheimer disease on the retina,…
Source: Retinal PhysicianCategories: Latest Headlines, OphthalmologyTweet-
EyePoint Pharmaceuticals and Rallybio Corporation announced a research collaboration to evaluate sustained delivery of Rallybio’s inhibitor of complement C5 using EyePoint’s proprietary Durasert technology. Read more in the Subspecialty News. https://t.co/zqgd1uqOQU https://t.co/eb4CgnMzcT
-
Awareness about biosimilar drugs in ophthalmology is lagging in the ophthalmic community, according to a market research study. Read more in the Subspecialty News. https://t.co/YaLG8pUvAe https://t.co/eXbcYAfZky